Latest Trustworthy News from Dr. Mercola - delivered straight to your inbox!

The Keto HDAC Myth — How One Paper May Have Misled Millions for a Decade

Analysis by Dr. Joseph Mercola

keto bhb hdac myth

Story at-a-glance

  • A 2013 Science paper claimed beta-hydroxybutyrate (BHB), the primary ketone body produced during ketosis, was a potent histone deacetylase (HDAC) inhibitor with powerful epigenetic benefits — this claim became the foundation of the keto movement's health narrative
  • A 2019 head-to-head comparison in Scientific Reports found that BHB showed no detectable HDAC inhibition in cell experiments, while butyrate (a different molecule produced by gut bacteria) demonstrates robust HDAC-inhibiting activity
  • Ketogenic diets can reduce colonic butyrate production by depleting fiber intake and diminishing butyrate-producing gut bacteria — the very diet designed to boost the "HDAC-inhibiting ketone" may be depleting the actual HDAC inhibitor
  • While BHB has legitimate benefits as an alternative fuel source and GPR109A receptor activator, the widespread claim that ketosis provides "epigenetic therapy" through HDAC inhibition appears to be scientifically unfounded
  • Standard oral butyrate supplements are mostly absorbed in the upper intestine before reaching the colon, where butyrate is needed, so delayed-release forms like microencapsulation are designed to release it farther along the digestive tract

For the past decade, the ketogenic diet community has promoted a compelling narrative: that entering ketosis produces beta-hydroxybutyrate (BHB), which acts as a powerful histone deacetylase (HDAC) inhibitor, unlocking profound epigenetic benefits that explain many of the diet's purported health advantages.

This story has been repeated by researchers, health influencers, and keto advocates worldwide, including prominent figures like Dr. Dominic D'Agostino from the University of South Florida, whose work on ketogenic diets and exogenous ketones has been featured on countless podcasts and media outlets.1 The epigenetic narrative became central to explaining why ketosis seemed to help with everything from inflammation to neurodegeneration to cancer. There's just one problem: it appears to be wrong.

The Paper That Started It All

In December 2012, a landmark paper was published online in the prestigious journal Science by Shimazu and colleagues.2 The study, titled "Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor," made a bold claim: The ketone body d-β-hydroxybutyrate (BHB) is an endogenous and specific inhibitor of class I histone deacetylases.

The paper reported that BHB inhibited HDAC1, HDAC3, and HDAC4 in a dose-dependent manner, with IC50 values in the low millimolar range — concentrations achievable during fasting or ketosis. The researchers showed that administration of BHB, fasting, or calorie restriction all increased global histone acetylation in mouse tissues, and that this was associated with increased expression of oxidative stress resistance genes like FOXO3A and MT2.

This was exactly the mechanistic explanation the keto community needed. HDAC inhibitors are an established class of cancer drugs, and they're also being studied for anti-inflammatory and neuroprotective effects. If BHB was a natural HDAC inhibitor produced during ketosis, it would explain why the ketogenic diet seemed to have such wide-ranging benefits.

The paper was cited over 2,000 times and became foundational to how keto advocates explained the diet's benefits. Prominent researchers began incorporating the HDAC inhibitor narrative into their lectures, papers, and media appearances. The story was simple and compelling: ketosis → BHB production → HDAC inhibition → epigenetic benefits → better health outcomes.

The 2019 Reckoning — When Scientists Actually Compared the Two Molecules

The problem is that butyrate — a short-chain fatty acid produced by gut bacteria when they ferment dietary fiber — is also an HDAC inhibitor. In fact, butyrate is a well-established HDAC inhibitor that has been studied for decades.3 And structurally, butyrate and BHB are remarkably similar, differing only by a hydroxyl group.

This similarity led researchers to wonder: When you actually compare the two molecules head-to-head using the same assays, do they perform equally?

In January 2019, a team of researchers published a study in Scientific Reports titled "Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule."4 Their findings challenged the BHB-as-HDAC-inhibitor narrative.

The researchers conducted a systematic comparison, evaluating histone acetylation levels, transcriptional regulation of metabolic and inflammatory genes, and cytokine secretion profiles across multiple cell types. Their conclusion was stark:

"We confirm that butyrate is a strong HDAC inhibitor, a characteristic we could not identify in R-β-hydroxybutyrate in vivo nor in vitro."

Even more concerning, the study found that while butyrate suppressed gene expression and LPS-induced secretion of several pro-inflammatory genes in endothelial cells, BHB actually "acted as a slightly pro-inflammatory molecule." This was the opposite of what the keto community had been claiming.

link in the keto HDAC story

Figure 1. A 2013 paper reported that BHB inhibits HDACs, but a 2019 head-to-head comparison found no detectable HDAC inhibition from BHB, while butyrate was a strong HDAC inhibitor.

What the Head-to-Head Comparison Revealed

The 2019 study tested BHB at concentrations significantly higher than butyrate — yet BHB still failed to promote histone acetylation. The researchers used multiple forms of BHB (the R-enantiomer, S-enantiomer, and racemic mixture) to ensure they weren't missing any activity. None showed HDAC inhibition.

In contrast, butyrate had an extensive impact on gene transcription in rat myotubes, upregulating PGC1α, CPT1b, mitochondrial sirtuins (SIRT3-5), and the mitochondrial antioxidative genes SOD2 and catalase. These are exactly the kinds of metabolic improvements that people attribute to ketosis — and in this cell study, butyrate, not BHB, produced them.

The researchers explicitly called for "a reassessment of R-β-hydroxybutyrate function as HDAC inhibitor and anti-inflammatory molecule." This wasn't a minor quibble — it was a direct challenge to the foundational claim of the ketogenic diet's epigenetic benefits.

Before examining the comparison table below, it's essential to understand one of the most important differences between these two molecules: their effects on regulatory T cells, or Tregs. These specialized immune cells function as the body's master peacekeepers, actively suppressing excessive immune responses and preventing your immune system from attacking your own tissues.

Without adequate Treg function, inflammation can run unchecked, autoimmune diseases can develop, and the body can remain in a state of chronic immune activation.

Tregs exert their calming influence by secreting anti-inflammatory cytokines like IL-10 and TGF-β, and by directly suppressing the activity of pro-inflammatory immune cells. The transcription factor Foxp3 is the master regulator that defines Treg identity; when Foxp3 is expressed, a T cell commits to the regulatory lineage and gains its inflammation-suppressing capabilities.

This is why the ability to induce Foxp3 expression and promote Treg differentiation is considered an important anti-inflammatory mechanism, and enhancing Treg function is an active area of drug development. As you'll see in the comparison below, butyrate promotes Treg differentiation in mouse studies and increases histone acetylation at the Foxp3 gene, while no comparable effect has been shown for BHB.5

The Honest Comparison — BHB vs. Butyrate

Claim BHB (Ketone) Butyrate (Fiber-Derived)
HDAC inhibitor Weak/undetectable Strong, well-documented
Anti-inflammatory Mixed; possibly pro-inflammatory in some contexts Robust anti-inflammatory effects
GPR109A agonist Yes Yes
Alternative fuel Yes (brain, heart, muscle) Yes (colonocytes specifically)
Treg induction Not shown Yes, in mouse studies — increases histone acetylation at the Foxp3 gene
IL-10 effects Unknown Upregulates IL-10 (master anti-inflammatory cytokine)
Practical delivery Keto diet, exogenous ketones, fasting Fiber fermentation; standard oral supplements mostly absorbed before reaching the colon; delayed-release forms designed for later release

Note: These findings are from laboratory or animal research and may not directly apply to human health.

The Cruel Irony — Keto Diets May Actually Reduce Your HDAC Inhibitor Levels

If the HDAC inhibitor story weren't damaging enough, there's an even more troubling irony: Ketogenic diets may actually reduce your body's production of the real HDAC inhibitor — butyrate.

Butyrate is produced in your colon when beneficial gut bacteria ferment dietary fiber. This requires two things: adequate fiber intake and a healthy population of butyrate-producing bacteria like Faecalibacterium prausnitzii, Roseburia, and Eubacterium rectale. Ketogenic diets can undermine both of these requirements.

A systematic review published in 2022 in Gastroenterology and Hepatology from Bed to Bench found that ketogenic diets persistently decrease Bifidobacterium abundance and reduce fecal short-chain fatty acids including butyrate.6 The review noted that "colonic health was the main concern raised by the included studies relating to the KD's microbial impacts, primarily ascribed to the negative impact on SCFA production."

Another 2024 study in 15 women with overweight and obesity found that a 6-week ketogenic diet significantly reduced fecal butyrate, propionate, acetate, and total SCFA levels.7 The researchers also observed decreased abundance of Bifidobacterium.

Laboratory research also suggests that BHB itself may directly inhibit Bifidobacterium growth.8 So not only does the low-fiber nature of keto diets starve butyrate-producing bacteria, but the very ketone bodies produced by the diet may further suppress beneficial bacterial populations.

This creates a bitter paradox: people following strict ketogenic diets to obtain "HDAC inhibitor benefits" from BHB may actually be depleting their levels of butyrate — the molecule that actually provides robust HDAC inhibition.

ketogenic diets lower butyrate

Figure 2. Ketogenic diets may lower butyrate by reducing fiber and beneficial gut bacteria, and BHB itself may inhibit Bifidobacterium growth.

Note: These findings are from research conducted in clinical settings. Results may not apply to all individuals.

Where BHB Still Has Legitimate Value

This isn't to say that BHB or ketogenic diets are worthless. There are legitimate, well-documented benefits that don't require HDAC inhibition:

1. Alternative fuel source — BHB provides energy for the brain, heart, and muscles when glucose is scarce. This is particularly valuable in epilepsy, where the ketogenic diet has a century of clinical evidence.

2. GPR109A activation — BHB does activate the GPR109A receptor (also known as HCA2), which is shared with butyrate and niacin. This provides some anti-inflammatory signaling, though through a different mechanism than HDAC inhibition.

3. Seizure control — Ketogenic diets are an established treatment for refractory epilepsy, though the mechanism may not be HDAC-related.

4. Metabolic signaling — Ketones signal fasting state and affect AMPK and other metabolic pathways.

5. Histone β-hydroxybutyrylation — BHB can be used for a different type of histone modification — β-hydroxybutyrylation rather than acetylation.9 This is a real phenomenon, though its functional significance is still being worked out, and it is not the same as HDAC inhibition.

6. NLRP3 inflammasome blocking — BHB blocks the NLRP3 inflammasome, an inflammatory pathway that doesn't depend on HDAC inhibition.10

Dr. D'Agostino's research on exogenous ketones for oxygen toxicity seizures in animals and for seizure disorders isn't affected by this debate. These applications don't require HDAC inhibition to work. But the broader narrative that "BHB is an epigenetic wonder molecule" needs serious revision.

The Oral Butyrate Problem — Why Standard Supplements Fall Short

If butyrate is the real HDAC inhibitor and keto diets reduce its production, can you simply take butyrate supplements?

Unfortunately, this approach faces a significant pharmacokinetic problem: Standard oral butyrate is absorbed almost entirely in the small intestine, before it can reach the colon where it's actually needed. As a result, little of it reaches the colon in meaningful concentrations.

As one research review noted: "orally administered free butyrate is taken up almost entirely by enterocytes in the proximal intestine and may not reach the colon."11 This means conventional butyrate supplements largely fail to deliver butyrate to the colonocytes that need it.

butyrate delivery

Figure 3. Butyrate made from fiber forms in the colon where it's needed, while standard oral butyrate is taken up almost entirely in the upper intestine.

Various strategies have been attempted to solve this problem, including enteric-coated tablets, microencapsulation, tributyrin (butyrate esterified to glycerol), and butyrylated starches. Some of these show modest improvements in colonic delivery, and colon-targeted forms have been tested in small trials,12,13 although more research is needed to confirm how much reaches the colon.

What This Means for the Keto Community

To be fair to Dr. D'Agostino and other keto researchers, the original 2013 Shimazu paper was published in Science — one of the world's most prestigious journals. It's not unreasonable that researchers and advocates built upon its claims. The paper appeared to provide a compelling mechanistic explanation for ketosis benefits.

But science is supposed to be self-correcting. The 2019 Chriett study in Scientific Reports directly challenged the foundational claim with side-by-side experimental evidence. Other studies, including a 2021 paper in Life Science Alliance, have similarly failed to confirm BHB's HDAC inhibitory activity, noting that "studies have since been unable to confirm an HDAC inhibitory activity for βOHB in various cell types."14

Yet the "BHB is an HDAC inhibitor" narrative continues to be promoted in podcasts, articles, and presentations. Searches for keto diet benefits still return claims about epigenetic regulation through HDAC inhibition. This represents a significant failure of scientific communication.

The ketogenic diet community owes it to the millions of people following their advice to update the narrative. Continuing to promote claims that later experiments haven't supported doesn't serve anyone's health — it only undermines trust in scientific guidance.

The Bottom Line

The story that ketosis provides epigenetic benefits through BHB's HDAC inhibition appears to be built on a foundation that has crumbled under experimental scrutiny. The well-established HDAC inhibitor your body produces is butyrate — a molecule made by gut bacteria from dietary fiber, not from fat metabolism.

Ironically, strict ketogenic diets that eliminate fiber may actually deplete butyrate production, undermining the very benefits people were seeking by entering ketosis. This doesn't mean ketogenic diets are without merit. But it does mean that the mechanistic story needs to be updated. Health claims should be based on the best available evidence — and when that evidence changes, the claims should change too.

That said, I no longer recommend ketogenic diets. Low-carb diets can lead to reductive stress, lower energy production, and physiological insulin resistance, and glucose is the preferred fuel for your cells. For most adults, I recommend 250 grams of carbohydrates a day.

For those seeking the true HDAC inhibition benefits that were attributed to BHB, the answer lies not in reducing carbohydrates, but in optimizing colonic butyrate levels. If your gut is compromised, though, fiber-rich foods can feed endotoxin-producing bacteria instead, so start with white rice and whole fruits. As your gut health improves, you’ll then be able to incorporate more fiber-rich vegetables and starches into your diet without problems.

The challenge is that some conventional butyrate formulations may release before reaching the colon. A delayed-release system like microencapsulation, designed for release farther along the digestive tract, is one way to approach a gap that:

• Ketogenic diets cannot provide (and may actually impair)

• Standard oral butyrate supplements miss (absorbed in the small intestine)

• Standard fiber supplements do inefficiently (dependent on microbiome composition)

The evidence has shifted. It's time for the keto community to update its story.

FAQs About BHB, Butyrate, and HDAC Inhibition

Q: Is beta-hydroxybutyrate (BHB) a meaningful HDAC inhibitor?

A: Early research suggested BHB acted as a histone deacetylase (HDAC) inhibitor, which fueled claims that ketosis delivered powerful epigenetic benefits. Later head-to-head studies failed to confirm this. Direct comparisons show BHB does not significantly inhibit HDACs in cell studies.

Q: What molecule actually provides strong HDAC inhibition in the body?

A: Butyrate, a short-chain fatty acid produced by gut bacteria when they ferment dietary fiber, is a well-established and potent HDAC inhibitor. In lab and animal studies, it increases histone acetylation, regulates gene expression, and reduces inflammation across multiple tissues.

Q: How did the original BHB-HDAC theory gain traction?

A: A 2013 paper in Science reported that BHB inhibited class I HDACs at concentrations seen during fasting or ketosis. The paper shaped a decade of keto-related messaging. Subsequent studies comparing BHB with butyrate didn't reproduce those findings.

Q: How do ketogenic diets affect butyrate production?

A: Ketogenic diets often reduce fiber intake and suppress beneficial gut bacteria that produce butyrate. Reviews and clinical studies show ketogenic diets lower fecal butyrate and other short-chain fatty acids, raising concerns about colonic and immune health.

Q: Where does BHB still provide real benefits?

A: BHB serves as an alternative fuel for the brain, heart, and muscles, activates the GPR109A receptor, and supports seizure control in epilepsy. It also participates in histone β-hydroxybutyrylation, a distinct process from HDAC inhibition. These benefits do not rely on HDAC suppression.


This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your health regimen.